# R1 Clinical-Safety Review — osteoblastoma (management narrative)

VERDICT: APPROVE

## 1. Safety
No unsafe, misleading, or over-absolute statements. Content is consistent with standard
management of a benign bone-forming tumor: surgery as the definitive modality, curettage for
non-aggressive lesions, wider/en bloc margins for aggressive or recurrent disease, and spinal
decompression + stabilization when neural structures are compromised. Critically, it does NOT
under-triage: it repeatedly flags the histologic/radiologic overlap with osteosarcoma, mandates
orthopedic-oncology referral before biopsy, urges expert bone-pathology review of atypical
specimens, and warns to re-exclude a missed/evolving osteosarcoma if behavior departs from the
benign course. This is the correct safety posture (the real hazard here is treating an
osteoblastoma-like osteosarcoma as benign) and it is handled well. No harm risk if followed.

## 2. Grounding
No fabricated or outdated regimen. There are zero drug names, trial names, or statistics to
misattribute. The narrative honestly states DeVita has no dedicated osteoblastoma management
section (only two passing mentions: chondrosarcoma-etiology aside and a bone-mass differential
list) and therefore labels every management claim as "general oncology standard, not from
DeVita's section on this disease." The clinical claims made are uncontroversial standard of care
for this benign entity. No claim is mis-attributed to DeVita.

## 3. Dose-free
Confirmed. No mg, mg/m2, AUC, Gy, or numbered schedule. Only digits are "12th" (edition number
in the source citation). Adversarial grep verdict concurs.

## 4. Scope
Appropriately hedged as decision-support: "standard," "preferred," "favored," "generally
avoided," "warrant referral" — no rigid directives. The benign nature and non-applicability of
the malignant lines-of-therapy framework are correctly explained rather than force-fit.

## 5. Adversarial flags
The .verdict.md returns CLEAN. The prior blocking defect (footer re-attributing the narrative to
DeVita) is confirmed FIXED — footer now reads "NOT sourced from DeVita ... needs manual sourcing."
No previously flagged issue remains present. The claims are clinically uncontroversial AND already
relabelled as general-standard, satisfying the approval condition.

## Open item (non-blocking for R1 clinical safety)
The draft self-flags "needs manual sourcing" against a dedicated bone-tumor reference (WHO
Classification of Tumours, Soft Tissue and Bone, or an orthopedic-oncology text). This is a
sourcing/provenance task, not a clinical-safety defect — the surgical-management claims are
standard of care. Recommend confirming against a bone-tumor-specific source before ship, but it
does not block R1.

goldens changed: no (intended: n/a — reference KB narrative, no engine/golden output touched)
